AR052156A1 - Fenil-metanonas bi- y triciclicas sustituidas para el tratamiento de trastornos neurologicos y neuropsiquiatricos - Google Patents

Fenil-metanonas bi- y triciclicas sustituidas para el tratamiento de trastornos neurologicos y neuropsiquiatricos

Info

Publication number
AR052156A1
AR052156A1 ARP050105207A ARP050105207A AR052156A1 AR 052156 A1 AR052156 A1 AR 052156A1 AR P050105207 A ARP050105207 A AR P050105207A AR P050105207 A ARP050105207 A AR P050105207A AR 052156 A1 AR052156 A1 AR 052156A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
halogen
substituted
neurological
treatment
Prior art date
Application number
ARP050105207A
Other languages
English (en)
Spanish (es)
Inventor
Synese Jolidon
Robert Narquizian
Roger David Norcross
Emmanuel Pinard
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR052156A1 publication Critical patent/AR052156A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP050105207A 2004-12-15 2005-12-13 Fenil-metanonas bi- y triciclicas sustituidas para el tratamiento de trastornos neurologicos y neuropsiquiatricos AR052156A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04106597 2004-12-15

Publications (1)

Publication Number Publication Date
AR052156A1 true AR052156A1 (es) 2007-03-07

Family

ID=35841863

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105207A AR052156A1 (es) 2004-12-15 2005-12-13 Fenil-metanonas bi- y triciclicas sustituidas para el tratamiento de trastornos neurologicos y neuropsiquiatricos

Country Status (20)

Country Link
US (1) US7375226B2 (enExample)
EP (1) EP1828200B1 (enExample)
JP (1) JP4709849B2 (enExample)
KR (1) KR100883003B1 (enExample)
CN (1) CN100586951C (enExample)
AR (1) AR052156A1 (enExample)
AT (1) ATE457989T1 (enExample)
AU (1) AU2005315914B2 (enExample)
BR (1) BRPI0519054A2 (enExample)
CA (1) CA2590316A1 (enExample)
DE (1) DE602005019465D1 (enExample)
ES (1) ES2338139T3 (enExample)
IL (1) IL183592A0 (enExample)
MX (1) MX2007006896A (enExample)
NO (1) NO20072833L (enExample)
NZ (1) NZ555476A (enExample)
RU (1) RU2007121768A (enExample)
TW (1) TWI299041B (enExample)
WO (1) WO2006063709A1 (enExample)
ZA (1) ZA200705044B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485637B2 (en) * 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
RU2338537C2 (ru) * 2006-01-25 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
KR101805914B1 (ko) 2007-03-12 2017-12-06 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
EP2527328A1 (en) 2008-04-01 2012-11-28 Abbott GmbH & Co. KG Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
EP2393878B1 (de) 2009-02-06 2012-12-12 Styrolution GmbH Thermoplastische formmassen auf basis von styrolcopolymeren und polyamiden mit verbesserter witterungsbeständigkeit
TW201038569A (en) * 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012031024A1 (en) * 2010-08-31 2012-03-08 Vanderbilt University Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mglur5 receptors
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
CN103889968A (zh) 2011-08-05 2014-06-25 艾伯维德国有限责任两合公司 氨基苯并二氢吡喃、氨基苯并二氢噻喃及氨基-1,2,3,4-四氢喹啉衍生物,包含这些化合物的药用组合物,及其在治疗中的用途
MX2014006004A (es) 2011-11-18 2015-04-16 Abbvie Deutschland Derivados de aminobenzociclohepteno, aminotetralina, aminoindano y fenalcilamina n-sustituidas, composiciones farmaceuticas que los contienen, y su uso en terapia.
CA2860008C (en) * 2011-12-22 2020-11-10 Dominique Swinnen Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013138565A1 (en) 2012-03-16 2013-09-19 Vitae Pharmaceuticals, Inc. Liver x receptor modulators
WO2013138568A1 (en) 2012-03-16 2013-09-19 Vitae Pharmaceuticals, Inc. Liver x reception modulators
ES2727815T3 (es) 2012-04-14 2019-10-18 Intra Cellular Therapies Inc Tratamiento del TEPT y de trastornos del control de impulsos
PL2968320T3 (pl) 2013-03-15 2021-05-17 Intra-Cellular Therapies, Inc. Związki organiczne
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
AU2014336154A1 (en) 2013-10-17 2016-04-28 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2016537323A (ja) 2013-10-17 2016-12-01 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミノクロマン誘導体、アミノチオクロマン誘導体およびアミノ−1,2,3,4−テトラヒドロキノリン誘導体、これらを含有する医薬組成物、および治療におけるこれらの使用
AU2014360452C1 (en) 2013-12-03 2019-05-16 Intra-Cellular Therapies, Inc. Novel methods
WO2015154030A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
KR20170012210A (ko) 2014-04-04 2017-02-02 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
IL309536B2 (en) 2016-01-26 2025-07-01 Intra Cellular Therapies Inc Pharmaceutical preparation for injection containing (Sa10, Rb6)-3-)8-(4-fluorophenoxy)propyl)-b6, 7, 8, 9, 10, 10a- hexahydro-H1- pyrido[3',4' :4,5]pyrrolo[1,2,3 -de]quinoxalin-2(H3)-one
US10688097B2 (en) 2016-03-25 2020-06-23 Intra-Cellular Therapies, Inc. Organic compounds
US11014925B2 (en) 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NOVEL COMPOSITIONS AND METHOD
JP2019513143A (ja) 2016-03-28 2019-05-23 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規塩類および結晶
JP7013454B2 (ja) 2016-10-12 2022-02-15 イントラ-セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
US10906906B2 (en) 2016-12-29 2021-02-02 Intra-Cellular Therapies, Inc. Organic compounds
JP7132939B2 (ja) 2017-03-24 2022-09-07 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規組成物および方法
US11427587B2 (en) 2017-07-26 2022-08-30 Intra-Cellular Therapies, Inc. Organic compounds
EP3658145A4 (en) 2017-07-26 2021-04-21 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
BR112020019119A2 (pt) 2018-03-23 2021-01-12 Intra-Cellular Therapies, Inc. Compostos orgânicos
IL279195B1 (en) 2018-06-06 2025-08-01 Intra Cellular Therapies Inc A method of making bis-tosylate salt of lumateparone
CA3102948A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
KR102778034B1 (ko) 2018-06-11 2025-03-12 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
JP2022500362A (ja) 2018-08-29 2022-01-04 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規組成物および方法
CN112584837A (zh) 2018-08-31 2021-03-30 细胞内治疗公司 新方法
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
US12358916B2 (en) 2018-12-17 2025-07-15 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
US12297200B2 (en) 2018-12-17 2025-05-13 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
MX2022000143A (es) 2019-07-07 2022-02-17 Intra Cellular Therapies Inc Metodos novedosos.
JP7261942B2 (ja) 2019-12-11 2023-04-20 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2423847A1 (de) * 1973-05-28 1975-01-02 Ciba Geigy Ag Neue sulfamoylbenzoesaeureamide
DE2611705A1 (de) * 1976-03-18 1977-09-22 Josef Dipl Chem Dr Rer N Klosa N-5-(nitrofurfuryliden-)-1-amino- hydantoin enthaltende kristalloesungsmittel
IT1176613B (it) 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
RU2124511C1 (ru) 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
JPH08325234A (ja) * 1995-05-30 1996-12-10 Yamanouchi Pharmaceut Co Ltd 安息香酸誘導体又はその塩
US6001854A (en) * 1996-05-31 1999-12-14 Allelix Neuroscience Inc. Pharmaceutical for treating of neurological and neuropsychiatric disorders
EE200000482A (et) * 1998-03-06 2002-02-15 Janssen Pharmaceutica N.V. Glütsiini ülekannet pärssiva ühendi kasutamine ravimi valmistamiseks, ühend, seda sisaldav kompositsioon ning meetod ühendi ja kompositsiooni valmistamiseks
WO1999045011A1 (en) * 1998-03-06 1999-09-10 Janssen Pharmaceutica N.V. Glycine transport inhibitors
CA2406652A1 (en) * 2000-04-20 2001-11-01 Nps Allelix Corp. Aminopiperidines for use as glyt-1 inhibitors
GB0021419D0 (en) 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
ATE449090T1 (de) 2001-07-02 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
WO2003035602A1 (en) 2001-10-25 2003-05-01 Sankyo Company, Limited Lipid modulators
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
WO2004037800A1 (en) 2002-10-22 2004-05-06 Glaxo Group Limited Aryloxyalkylamine derivates as h3 receptor ligands
UA85194C2 (ru) * 2003-08-11 2009-01-12 Ф.Хоффманн-Ля Рош Аг Пиперазины с or-замещенной фенильной группой и их применение как ингибиторов glyt 1
JP4563386B2 (ja) * 2003-09-09 2010-10-13 エフ.ホフマン−ラ ロシュ アーゲー 精神病の処置のためのグリシン取り込み阻害剤としての1−(2−アミノ−ベンゾール)−ピペラジン誘導体
NZ545613A (en) * 2003-09-09 2009-11-27 Hoffmann La Roche 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses

Also Published As

Publication number Publication date
CN100586951C (zh) 2010-02-03
KR100883003B1 (ko) 2009-02-12
AU2005315914B2 (en) 2011-03-03
TWI299041B (en) 2008-07-21
WO2006063709A1 (en) 2006-06-22
MX2007006896A (es) 2007-06-26
ES2338139T3 (es) 2010-05-04
EP1828200B1 (en) 2010-02-17
JP4709849B2 (ja) 2011-06-29
AU2005315914A1 (en) 2006-06-22
US7375226B2 (en) 2008-05-20
IL183592A0 (en) 2007-09-20
ZA200705044B (en) 2008-09-25
BRPI0519054A2 (pt) 2008-12-23
JP2008523126A (ja) 2008-07-03
ATE457989T1 (de) 2010-03-15
DE602005019465D1 (de) 2010-04-01
CA2590316A1 (en) 2006-06-22
EP1828200A1 (en) 2007-09-05
RU2007121768A (ru) 2009-01-27
TW200634017A (en) 2006-10-01
US20060128713A1 (en) 2006-06-15
KR20070086196A (ko) 2007-08-27
CN101076532A (zh) 2007-11-21
NO20072833L (no) 2007-07-17
NZ555476A (en) 2009-09-25

Similar Documents

Publication Publication Date Title
AR052156A1 (es) Fenil-metanonas bi- y triciclicas sustituidas para el tratamiento de trastornos neurologicos y neuropsiquiatricos
AR054799A1 (es) Derivados de oxindol
CR7496A (es) Piridinoilpiperidinas como agonistas de 5- ht1f
CO5690643A2 (es) Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
AR049551A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la beta-secretasa
AR040278A1 (es) Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
NO20072643L (no) Fenylpiperazinmethanonderivater
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
PE20061156A1 (es) Derivados de benzamida como agentes inhibidores del transportador de glicina
CL2009001146A1 (es) Compuestos derivados de 5-(5-(2-(3,5-bis(trifluorometil)fenil)-n,2-dimetilpropanoamida)-4-(4-fluoro-2-metilfenil)piridin-2-il)pirrolidin-2-carboxamida, antagonistas de los receptores nk-1; composicion farmaceutica; y uso del compuesto para el tratamiento de la depresion; ansiedad, trastornos del sueño o emesis.
PE20070069A1 (es) Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a
AR037611A1 (es) Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden
AR041376A1 (es) Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia
PE20051152A1 (es) Antagonistas del receptor de acetilcolina muscarinico m3
AR068381A1 (es) Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6
CY1108837T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5
ECSP077394A (es) Compuestos aromáticos de arilsulfonilmetil o arilsulfonamida sustituida apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
PE20080206A1 (es) Derivados de aril y heteroaril-etil-acilguanidina como inhibidores de renina
CO4990949A1 (es) Derivados de imidazol y su preparacion .
AR055666A1 (es) Inhibidores inntr
UY26147A1 (es) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil-aminometilcromano.
AR052553A1 (es) Derivados de benzoil -tetrahidropiridina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal